4559 — Zeria Pharmaceutical Co Balance Sheet
0.000.00%
- ¥102bn
- ¥121bn
- ¥76bn
- 92
- 63
- 94
- 97
Annual balance sheet for Zeria Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9,005 | 9,797 | 11,704 | 16,219 | 20,324 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 13,239 | 13,497 | 16,153 | 17,420 | 21,080 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 35,020 | 37,314 | 41,664 | 48,204 | 57,809 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 23,125 | 23,634 | 23,139 | 24,591 | 26,518 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 104,156 | 121,860 | 124,282 | 135,035 | 150,534 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 41,070 | 53,797 | 44,193 | 47,158 | 54,518 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 51,645 | 65,875 | 69,388 | 69,585 | 70,911 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 52,510 | 55,985 | 54,895 | 65,450 | 79,623 |
Total Liabilities & Shareholders' Equity | 104,156 | 121,860 | 124,282 | 135,035 | 150,534 |
Total Common Shares Outstanding |